Australia's Immuron rises as company seeks partnership for new drug
BUZZ-Australia's Immuron rises as company seeks partnership for new drug ** Shares of Australia's Immuron IMC.AX rise 11.1% to A$0.040, hitting their highest level since June 4
** Stock marks its biggest intraday pct gain since June 1
** The biopharmaceutical company says it is employing an advisory firm to help seek a partner to support clinical and commercial development of IMM-529
** The IMM-529 is a product that can treat/prevent Clostridioides difficile infection, a contagious bacterial infection of the large intestine
** Immuron stock up 11.1%, YTD
(Reporting by Shravya Marakini in Bengaluru)
Recent news on Immuron
See all newsBrief: Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Australia's Immuron hits near 1.5-month high on distribution deal in US
Brief: Immuron Executes Exclusive Distribution Agreement For Proibs In The United States
Brief: Immuron Reports FY26 Preliminary Results
Brief: Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 Million